Denmark· DK-28104859911
Vepesid
A etoposide product containing etoposid, registered in Denmark by Orifarm A/S. The same ATC class is registered in 17 of our 19 countries.
Checked against Danish Medicines Agency (Denmark) on
Informational only — not a medical device.
Where it is registered
Etoposide is registered in 17 of 19 countries.
Countries holding a registration under ATC L01CB01 (etoposide), each read from that country’s own register.
- This record: Denmark, from Danish Medicines Agency (Denmark)
- 10 of them publish a price we can compare per daily dose
Etoposide · ATC L01CB01
17 / 19 countries
- Belgiumprice
- Canada
- Czechiaprice
- Denmark
- Finlandprice
- Franceprice
- Germany
- Icelandprice
- Ireland
- Italyprice
- Netherlands
- Norwayprice
- Polandprice
- Sweden
- Switzerlandprice
- United Kingdom
- United Statesprice
Price per daily dose
What a daily dose of etoposide costs, country by country.
Normalised to the WHO defined daily dose (50 mg), the median price runs from $9.95 in France to $18.65 in Switzerland — a ×1.9 gap.
- 2 markets with a comparable price for this class
- Public list prices, converted to USD at the rate date shown
Etoposide · price per daily dose (50 mg)
USD · FX 28 Sept 2026
- CH Switzerland$18.65
- FR France$9.95
The record
At a glance
Danish Medicines Agency (Denmark)- Active substance
- ETOPOSID
- Manufacturer
- Orifarm A/S
- Country
- Denmark (DK)
- ATC code
- L01CB01
- ATC class
- Etoposide
- Defined daily dose
- 50 mg, O
- Reimbursed
- Not published by this register
- Source register
- Danish Medicines Agency (Denmark)
- Last checked
- September 30, 2026
Packs & prices · 1
- dk_varenummer28104859911
Regulatory notes
No shortage, Orange Book or US label notes for this record.
Interactions
576 interactions on record for etoposide.
Graded by severity as the source publishes them — 30 severe. Severity grades are free for everyone; mechanism and management come with Growth.
- Severity for every pair — free, no plan needed
- The source, licence and sync date on every record
- Mechanism and what to do for each pair — Growth plan
Etoposide · interactions on record
576 records
- 30 severe
- 290 moderate
- 21 minor
- 235 info
Most severe, free to view
- CladribineL01BB04severe
- AprepitantA04AD12moderate
- RolapitantA04AD14moderate
- EliglustatA16AX10moderate
- Interaction severity from DDInter 2.0 (Xiong G. et al., Nucleic Acids Res.), licensed CC BY-NC 4.0 — free for non-commercial use only; not covered by the Drug Database commercial licence.
Same class
Other records under L01CB01
Etoposide, as other registers publish it.
Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of Danish Medicines Agency (Denmark). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.
For developers
The same record over the API, and the raw payload
GET /v1/drugs/bc51c1a3-d61e-4357-b3e6-1dd69f770860 GET /v1/drugs/bc51c1a3-d61e-4357-b3e6-1dd69f770860?format=fhir
Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.
{
"form": "kapsler, bløde",
"source": "dkma",
"strength": "50 mg",
"auth_role": "DKMA",
"dk_drugid": "28104859911",
"substance": "ETOPOSID",
"auth_procedure": "Par-Imp",
"in_medicinpriser": true,
"registration_date_serial": "40682"
}See everything about etoposide.
This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.